Therapeutic vaccination strategies to treat nasopharyngeal carcinoma

Graham S. Taylor*, Neil M. Steven

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

20 Citations (Scopus)


Epstein-Barr virus (EBV) infects most people worldwide. EBV has oncogenic potential and is strongly associated with several lymphomas and carcinomas, including nasopharyngeal carcinoma (NPC), that together total 200,000 cases of cancer each year. All EBV-associated cancers express viral proteins that allow highly selective immunotherapeutic targeting of the malignant cells. A number of therapeutic EBV vaccines have been tested in clinical trials with evidence of immune boosting and clinical responses in NPC patients. Therapeutic vaccination could be used after adoptive T-cell transfer to increase and sustain the number of infused T-cells or combined with immunotherapies acting at different stages of the cancer immunity cycle to increase efficacy. The therapeutic EBV vaccines tested to date have been well tolerated with minimal off-target toxicity. A safe therapeutic vaccine that was also able to be mass produced could, in principle, be used to vaccinate large numbers of patients after first line therapy to reduce recurrence.

Original languageEnglish
Article number23
JournalChinese Clinical Oncology
Issue number2
Publication statusPublished - 1 Apr 2016


  • Immunotherapy
  • PD-L1
  • Protein Death receptor 1 (PD1)
  • Tumor

ASJC Scopus subject areas

  • Oncology
  • General Medicine


Dive into the research topics of 'Therapeutic vaccination strategies to treat nasopharyngeal carcinoma'. Together they form a unique fingerprint.

Cite this